TY - JOUR
T1 - Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations
AU - Chernin, Gil
AU - Vega-Warner, Virginia
AU - Schoeb, Dominik S.
AU - Heeringa, Saskia F.
AU - Ovunc, Bugsu
AU - Saisawat, Pawaree
AU - Cleper, Roxana
AU - Ozaltin, Fatih
AU - Hildebrandt, Friedhelm
AU - Arbeiter, A.
AU - Bakkalogulu, A.
AU - Benz, M.
AU - Bockenhauer, D.
AU - Bogdanovic, R.
AU - Chandha, V.
AU - Ettenger, R.
AU - Ghossein, C.
AU - Goldberg, A.
AU - Heiliczer, J.
AU - Hooper, D.
AU - Hoppe, B.
AU - Jenkins, R.
AU - Kaplan, B.
AU - Kemper, M. J.
AU - Konrad, M.
AU - London, R.
AU - Mache, C.
AU - Mansoor, O.
AU - Mayr, M.
AU - Neuhaus, T.
AU - Plank, C.
AU - Reusz, G.
AU - Rinat, C.
AU - Seeman, T.
AU - Strecker, M.
AU - Taranta-Janusz, K.
AU - Weigel, F.
AU - Zolotnitskaya, A.
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Background and objectives: The risk of developing Wilms tumor (WT) can be present or absent in patients with nephrotic syndrome (NS) caused by WT1 mutations. Here, the genotype/phenotype correlation regarding the outcome and risk for WT in 52 patients from 51 families with NS due to WT1 mutations is described. Design, setting, participants, & measurements: This study followed 19 patients with mutations in intron 9 splice donor site (KTS mutations), 27 patients with missense mutations, 4 patients with nonsense mutations, 1 patient with a splice site mutation in intron 8, and 1 patient with a deletion. Results: Twenty-four different WT1 mutations were detected. Sixteen of the 19 patients with KTS mutations were females. These patients had isolated NS if karyotype was 46,XX and Frasier syndrome if karyotype was 46,XY. Patients with KTS mutations presented at a significantly older age and with a slower progression toward chronic kidney disease (CKD) stage 5, compared with missense mutations. Patients with nonsense mutations presented initially with WT. Six patients with missense mutations developed WT after the diagnosis of NS (interval-range from NS onset to WT of 0.1 to 1.4 years). Conclusions: (1) KTS mutations cause isolated NS with absence of WT in 46,XX females. (2) KTS mutations cause Frasier syndrome with gonadoblastoma risk in 46,XY phenotypic females. (3) KTS mutations cause NS with a slower progression when compared with missense mutations. (4) Missense mutations can occur with and without WT. (5) WT1 analysis is important in young patients with NS for early detection and tumor prophylaxis.
AB - Background and objectives: The risk of developing Wilms tumor (WT) can be present or absent in patients with nephrotic syndrome (NS) caused by WT1 mutations. Here, the genotype/phenotype correlation regarding the outcome and risk for WT in 52 patients from 51 families with NS due to WT1 mutations is described. Design, setting, participants, & measurements: This study followed 19 patients with mutations in intron 9 splice donor site (KTS mutations), 27 patients with missense mutations, 4 patients with nonsense mutations, 1 patient with a splice site mutation in intron 8, and 1 patient with a deletion. Results: Twenty-four different WT1 mutations were detected. Sixteen of the 19 patients with KTS mutations were females. These patients had isolated NS if karyotype was 46,XX and Frasier syndrome if karyotype was 46,XY. Patients with KTS mutations presented at a significantly older age and with a slower progression toward chronic kidney disease (CKD) stage 5, compared with missense mutations. Patients with nonsense mutations presented initially with WT. Six patients with missense mutations developed WT after the diagnosis of NS (interval-range from NS onset to WT of 0.1 to 1.4 years). Conclusions: (1) KTS mutations cause isolated NS with absence of WT in 46,XX females. (2) KTS mutations cause Frasier syndrome with gonadoblastoma risk in 46,XY phenotypic females. (3) KTS mutations cause NS with a slower progression when compared with missense mutations. (4) Missense mutations can occur with and without WT. (5) WT1 analysis is important in young patients with NS for early detection and tumor prophylaxis.
UR - http://www.scopus.com/inward/record.url?scp=77957315050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957315050&partnerID=8YFLogxK
U2 - 10.2215/CJN.09351209
DO - 10.2215/CJN.09351209
M3 - Article
C2 - 20595692
AN - SCOPUS:77957315050
SN - 1555-9041
VL - 5
SP - 1655
EP - 1662
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 9
ER -